sunitinib can lead to a prolonged and complete pathological response with a significant improvement of quality of life. 1 Laurence Albiges et al: Complete ...
ANTICANCER RESEARCH 33: 2245-2342 (2013) sunitinib can lead to a prolonged and complete pathological response with a significant improvement of quality of life. 1 Laurence Albiges et al: Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clinical Oncol 30(5), 2012. 2 Rini BI et al: Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5(3): 232-234, 2006. 3 Karellas ME, Jang TL, Kagiwada MA, Kinnaman MD, Jarnagin WR and Russo P: Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU Int 103(2): 160-164, 2009. 66 INVESTIGATING THE ROLE OF FDG-PET/CT FOR PREOPERATIVE LYMPH-NODE STAGING OF BLADDER CANCER: OUR PRELIMINARY EXPERIENCE Andrea Buffardi1, Antonella Parente2, Paolo Destefanis1, Marilena Bellò2, Andrea Bosio1, Ettore Dalmasso1, Eugenio Alessandria1, Paolo Gontero1, Gianni Bisi2, Bruno Frea1 1Clinica Urologica, Azienda Ospedaliera Città della Salute e della Scienza, Sede Molinette, Torino; 2S.c. Medicina Nucleare 2, Azienda Ospedaliera Città della Salute e Della Scienza, Sede Molinette, Torino, Italy
Introduction: In patients with nonmetastatic invasive bladder cancer (T2 or higher, M0) or recurrent high-risk non-muscle invasive disease (T1G3 with or without Tis, M0), locoregional lymph node metastasis is an important prognostic factor. The standard imaging modalities for staging (computed tomography [CT] or magnetic resonance imaging [MRI]) have an accuracy range of 70-90% for lymph-node staging. Fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) has been approved for imaging in many malignancies but not for bladder cancer. This study investigated the value of FDGPET/CT for preoperative lymph-node staging of patients with MIBC. We present our preliminary results. Patients and Methods: Between September 2012 and February 2013, 10 patients (8 male, 2 female) with bladder cancer underwent FDG-PET/CT and a thoraco-abdominal CT scan. Four patients were found to be recurrent T1G3 at TUR-B, five T2G3 and one T2G2. Independently from the results for lymphnode status at FDG-PET/CT or at abdominal CT scan, all patients underwent radical cystectomy and lymphadenectomy. Results of FDG-PET/CT and CT for N-staging were compared to 2290
histopathology findings. Complete data are available for 8 patients. Results: Among the 8 patients, 3 patients had metastatically involved locoregional lymph nodes, diagnosed on histopathology. In all these patients, the lymph-nodes demonstrated increased FDG uptake on PET/CT; the same nodes were not considered as metastatic at abdominal CT scan. Five patients had lymph-nodes with a normal FDG uptake on PET/CT: these nodes were found nonmetastatic at histopathology. Only 1 patient had nodes suspected for metastases at CT scan but not at FDGPET/CT: these lymphnodes were found nonmetastatic at histopathology. The accordance between histopathology and FDG-PET/CT findings was 100%. Discussion and Conclusion: Our preliminary data show that FDG-PET/CT may provide better accuracy in N-staging of bladder cancer; our study is still ongoing because a larger sample (at least 50-75 patients) is needed. According to our results and to data in the Literature, larger prospective studies are needed to elucidate the effective role of FDG-PET/CT in N-staging of bladder cancer. 1 Lu YY, Chen JH, Liang JA, Wang HY, Lin CC, Lin WY and Kao CH: Clinical value of FDG-PET or PET/CT in urinary bladder cancer: a systemic review and metaanalysis. Eur J Radiol Sep 5, 2011. 2 Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lessage K and Werbrouck P: FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 57: 641-647, 2010. 3 Lodde M, Lacombe L, Friede J, Morin F, Saourine A and Fradet Y: Evaluation of fluorodeoxyglucose positronemission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 106: 658-663, 2010. 67 DECISION AIDS: HOW TO HELP THE PATIENTS CHOOSE THE “BEST” OPTION FOR LOCALIZED PROSTATE CANCER Silvia Villa1, Lara Bellardita1, Tiziana Magnani1, Daniela Villani1, Silvia Stagni2, Davide Biasoni2, Sara Morlino3, Sergio Villa3, Riccardo Valdagni4 1Programma 2Urologia,
Prostata,
3Radioterapia
Oncologica 1, Prostata, Radioterapia Oncologica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy 4Programma
According to international guidelines, patients diagnosed with prostate cancer (PCa) should be informed of the different but equally effective therapeutic/observational options. PCa strategies also differ in terms of risks and
